

## Who can administer

May be administered by registered competent doctor or nurse/midwife

## Important information

- Consider premedication (antihistamine and/or paracetamol) if infusion-related reactions are anticipated (ref 1)
- In order to improve the traceability of biological medicinal products, **the name and the batch number of the administered product should be clearly recorded**
- Confirm patient does **not have a history of current or recent infection**, or recent exposure to chicken pox or TB
- **Immunisations**
  - Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines
  - If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab
  - Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment

## Available preparations

Skyrizi 600 mg per 10mL vial

## Reconstitution

Already in solution

**Dilute further prior to administration**

## Infusion fluids

Sodium chloride 0.9% or Glucose 5%

## Methods of intravenous administration

**Intermittent intravenous infusion (using an electronically controlled infusion device)**

- This is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate personal protective equipment. (ref 1)
- **Prepare and administer according to the following table**

Indication	Intravenous induction dose	Number of 600mg/10mL vials	Volume of infusion fluid	Infusion duration
<b>Crohn's disease</b>	600mg	1	100, 250 or 500mL	at least 60 minutes
<b>Ulcerative colitis</b>	1200mg	2	250 or 500mL	at least 120 minutes
<b>Do not shake the solution in the vial or in the infusion bag</b>				<b>Â</b>

# Dose in adults

## **Crohn's disease**

- Give 600mg at week 0,4 and 8
- Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

## **Â Ulcerative colitis**

- Give 1200mg at week 0,4 and 8
- Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

## **Renal or hepatic impairment**

- No dose adjustment required

# Storage

Store between 2 and 8<sup>0</sup>C

# References

SPC July 2024

1: Injectable medicines guide, Medusa, Downloaded Oct 2024

# Therapeutic classification

Immunosuppressant, interleukin inhibitor